Quarterly ResultAug 5, 2026, 05:05 PM
Caris Life Sciences Q2 Revenue $263.7M; Net Loss $(0.6M)
AI Summary
Caris Life Sciences reported a significant improvement in its financial performance for the second quarter and first half of 2026. Total revenue for Q2 2026 increased by 45.4% to $263.7 million, with net loss narrowing substantially to $(0.6) million from $(71.8) million in the prior year. For the first six months of 2026, total revenue grew 58.7% to $479.9 million, and the company generated $61.4 million in net cash from operating activities, a turnaround from cash used in the previous year.
Key Highlights
- Q2 2026 total revenue increased 45.4% to $263.7 million.
- Q2 2026 net loss significantly improved to $(0.6) million from $(71.8) million YoY.
- H1 2026 total revenue grew 58.7% to $479.9 million.
- H1 2026 net loss improved to $(1.1) million from $(174.4) million YoY.
- Net cash provided by operating activities was $61.4 million for H1 2026.
- Molecular profiling services revenue rose 54.9% to $252.3 million in Q2 2026.
- Cash, cash equivalents, and restricted cash totaled $690.9 million as of June 30, 2026.
Price Impact
More from CAI